Tinzaparin is a low-molecular-weight heparin (LMWH) with antithrombotic properties. It has FDA-approved labeling for use in the treatment of acute symptomatic deep-vein thrombosis (DVT ...

BACKGROUND: Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are approved for venous thromboembolism (VTE) prophylaxis. Which agent is superior remains controversial.

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous ...

Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and ...

Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite ...

Getty ImagesA team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual ...

Using our AlphaScreen assay, with a Z-factor of 0.65, we screened ∼300 compounds and discovered a small-molecule compound (herein referred to as A9), which can disrupt the tau-heparin interaction with ...

In addition, the market is driven by developments in heparin formulations, particularly fractionated and low-molecular-weight variants for thrombosis management. Key patient groups include the ...

Although low-molecular-weight heparin (LMWH) has been recommended to prevent venous thromboembolism, its anticoagulant and anti-inflammatory effects in sepsis remain controversial. Owing to the ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose ...

The beads are covered in heparin, a substance similar to a molecule found inside blood vessels that pathogens bind to. When blood flows through the device, the beads mimic the inner walls of blood ...